Learn

A fragility fracture can dramatically change a patient's quality of life¹ – yet osteoporosis remains one of the most underdiagnosed and undertreated conditions in general practice.² With management options having evolved substantially,³ now is the time to update your approach. In this webinar, Professor Peter Ebeling distills the latest Osteoporosis Position Statement⁴ into a practical, risk-based prescribing framework — covering treatment initiation, specialist referral indications, long-term continuation, the appropriateness of pausing treatment, and strategies for communicating fracture risk to patients. The second half of the webinar is dedicated entirely to Q&A, giving you direct insights from one of Australia's leading osteoporosis experts to address the questions you encounter in everyday practice. 

References: 

1. Cooper C. Am J Med 1997;103:12S-17S 
2. Naik-Panvelkar P, et al. BMC Fam Pract 2020;21(1):32 
3. Subarajan P, et al. Endocrinol Metab Clin North Am 2024 ;53:497-512 
4. Healthy Bones Australia. Position Statement on the Management of Osteoporosis, November 2025. Available from:  [Accessed 12 May 2026] 

Learning Outcomes

1. Determine which patients meet criteria for an osteoporosis diagnosis and require pharmacological treatment
2. Describe the risk-based approach to osteoporosis treatments as outlined in the RACGP Osteoporosis Guidelines and Healthy Bones Australia Position Statement
3. Compare the risks associated with continuing osteoporosis treatment versus stopping treatment
4. Communicate to patients the connection between osteoporosis and fracture, and describe the benefits and risks of treatment.

Details